Progenity Announces Successful Transfer of Liquid Biopsy Technologies

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy.

Read more at globenewswire.com